TGFB1 and glioblastoma: The unique immune-privileged microenvironment due to the inherent expression of immunosuppressive cytokines, such as PD-1, TGF-β, and IL-10, and the lack of antigen-presenting cells (APCs) in the CNS present obstacles for the efficacy of immunotherapy in glioblastoma (GBM) (13).